DE69522716T2 - Verbesserung der glukosetoleranz - Google Patents
Verbesserung der glukosetoleranzInfo
- Publication number
- DE69522716T2 DE69522716T2 DE69522716T DE69522716T DE69522716T2 DE 69522716 T2 DE69522716 T2 DE 69522716T2 DE 69522716 T DE69522716 T DE 69522716T DE 69522716 T DE69522716 T DE 69522716T DE 69522716 T2 DE69522716 T2 DE 69522716T2
- Authority
- DE
- Germany
- Prior art keywords
- glucose tolerance
- compound
- diabetes mellitus
- enantiomers
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 34
- 239000008103 glucose Substances 0.000 title claims abstract description 34
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 3
- UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 15
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 13
- 230000001575 pathological effect Effects 0.000 claims description 10
- KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 150000004682 monohydrates Chemical class 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 6
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 6
- 229960003466 sibutramine hydrochloride Drugs 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- -1 N,N-dimethyl-2-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride Chemical compound 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Polyesters Or Polycarbonates (AREA)
- Lubricants (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/190,924 US5459164A (en) | 1994-02-03 | 1994-02-03 | Medical treatment |
| PCT/US1995/001190 WO1995020949A1 (en) | 1994-02-03 | 1995-02-03 | Improving glucose tolerance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69522716D1 DE69522716D1 (de) | 2001-10-18 |
| DE69522716T2 true DE69522716T2 (de) | 2002-05-29 |
Family
ID=22703362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69522716T Expired - Lifetime DE69522716T2 (de) | 1994-02-03 | 1995-02-03 | Verbesserung der glukosetoleranz |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US5459164A (https=) |
| EP (1) | EP0814788B1 (https=) |
| JP (1) | JPH10503166A (https=) |
| KR (1) | KR100339874B1 (https=) |
| CN (1) | CN1070698C (https=) |
| AT (1) | ATE205390T1 (https=) |
| AU (1) | AU694761B2 (https=) |
| CA (1) | CA2182620C (https=) |
| DE (1) | DE69522716T2 (https=) |
| DK (1) | DK0814788T3 (https=) |
| ES (1) | ES2166817T3 (https=) |
| IL (1) | IL112515A (https=) |
| PH (1) | PH31220A (https=) |
| PT (1) | PT814788E (https=) |
| TW (1) | TW314466B (https=) |
| WO (1) | WO1995020949A1 (https=) |
| ZA (1) | ZA95814B (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9619757D0 (en) * | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
| GB9619961D0 (en) * | 1996-09-25 | 1996-11-13 | Knoll Ag | Medical treatment |
| GB9619962D0 (en) * | 1996-09-25 | 1996-11-13 | Knoll Ag | Medical treatment |
| GB9727131D0 (en) | 1997-12-24 | 1998-02-25 | Knoll Ag | Therapeutic agents |
| US6476078B2 (en) * | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
| US6339106B1 (en) | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
| US6974838B2 (en) * | 1998-08-24 | 2005-12-13 | Sepracor Inc. | Methods of treating or preventing pain using sibutramine metabolites |
| US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| US6323242B1 (en) | 1998-12-02 | 2001-11-27 | Peter Sterling Mueller | Treatment of disorders secondary to organic impairments |
| US6696495B2 (en) | 1998-12-02 | 2004-02-24 | Snowden Pharmaceuticals, Llc | Treatment of disorders secondary to organic impairments |
| BG65170B1 (bg) * | 1999-03-17 | 2007-05-31 | Knoll Gmbh | Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето |
| AU3757800A (en) * | 1999-03-19 | 2000-10-09 | Abbott Gmbh & Co. Kg | Method of controlling weight gain associated with therapeutic drugs |
| WO2000056321A1 (en) | 1999-03-19 | 2000-09-28 | Knoll Pharmaceutical Company | Treatment of hyperactivity disorders |
| WO2000056309A1 (en) * | 1999-03-19 | 2000-09-28 | Knoll Pharmaceutical Company | Method of treating sexual dysfunction |
| AU3894500A (en) * | 1999-03-19 | 2000-10-09 | Knoll Pharmaceutical Company | Prevention of cardiovascular disease |
| US6552087B1 (en) | 1999-03-19 | 2003-04-22 | Abbott Gmbh & Co. Kg | Therapeutic agent comprising (+)-sibutramine |
| JP2002539252A (ja) * | 1999-03-19 | 2002-11-19 | クノール・ゲー・エム・ベー・ハー | 胆石の治療 |
| US6803387B1 (en) * | 1999-03-19 | 2004-10-12 | Abbott Gmbh & Co. Kg | Treatment of neuropathic pain or fibromyalgia |
| US6403650B1 (en) * | 1999-03-19 | 2002-06-11 | Knoll Pharmaceutical Company | Treatment of pulmonary hypertension |
| EP1169029B1 (en) * | 1999-03-19 | 2005-05-04 | Abbott GmbH & Co. KG | Use of sibutramine or its derivative for the treatment of sleep disorders |
| WO2000056319A1 (en) | 1999-03-19 | 2000-09-28 | Knoll Pharmaceutical Company | Treatment of orthostatic hypotension |
| IL145238A0 (en) * | 1999-03-19 | 2002-06-30 | Knoll Gmbh | Treatment of osteoarthritis |
| WO2000056311A1 (en) * | 1999-03-19 | 2000-09-28 | Knoll Pharmaceutical Company | Control of metabolism |
| AU3896900A (en) * | 1999-03-19 | 2000-10-09 | Knoll Pharmaceutical Company | Treatment of pain |
| WO2000056310A1 (en) * | 1999-03-19 | 2000-09-28 | Knoll Pharmaceutical Company | Treatment of chronic fatigue syndrome |
| US6372797B1 (en) | 1999-03-19 | 2002-04-16 | Knoll Pharmaceutical Company | Treatment of menstrual function |
| MXPA01009470A (es) * | 1999-03-19 | 2004-03-19 | Knoll Gmbh | Tratamiento de ciertos canceres asociados con el aumento de peso. |
| GB9914744D0 (en) * | 1999-06-24 | 1999-08-25 | Knoll Ag | Therapeutic agents |
| US6399826B1 (en) | 1999-08-11 | 2002-06-04 | Sepracor Inc. | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
| GB9926251D0 (en) * | 1999-11-06 | 2000-01-12 | Knoll Ag | Pharmaceutical formulation |
| US6232347B1 (en) | 2000-03-17 | 2001-05-15 | Knoll Pharmaceutical Company | Treatment of osteoarthritis |
| US6610887B2 (en) | 2001-04-13 | 2003-08-26 | Sepracor Inc. | Methods of preparing didesmethylsibutramine and other sibutramine derivatives |
| US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| US20040034101A1 (en) * | 2001-11-05 | 2004-02-19 | Cypress Bioscience, Inc. | Treatment and prevention of depression secondary to pain (DSP) |
| JP4278652B2 (ja) * | 2002-10-05 | 2009-06-17 | ハンミ ファーム． シーオー．， エルティーディー． | 結晶性シブトラミンメタンスルホン酸塩半水和物を含む医薬組成物 |
| US20050131074A1 (en) * | 2003-08-04 | 2005-06-16 | Beckman Kristen M. | Methods for treating metabolic syndrome |
| WO2006073292A1 (en) | 2005-01-06 | 2006-07-13 | Cj Corporation | Inorganic acid salts of sibutramine |
| KR100627687B1 (ko) * | 2005-04-20 | 2006-09-25 | 주식회사 씨티씨바이오 | 시부트라민 유리염기 함유 조성물 및 이의 제조방법 |
| US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| KR20080046601A (ko) * | 2006-11-22 | 2008-05-27 | 에스케이케미칼주식회사 | 보관안정성이 우수한 시부트라민 함유 포접복합체 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52768B1 (en) * | 1981-04-06 | 1988-02-17 | Boots Co Ltd | 1-arylcyclobutylalkylamine compounds useful as therapeutic agents |
| GB8531071D0 (en) * | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
| GB8704777D0 (en) * | 1987-02-28 | 1987-04-01 | Boots Co Plc | Medical treatment |
| DE3883606T2 (de) * | 1987-05-04 | 1994-01-20 | Lilly Co Eli | Verwendung von Fluoxetin zur Behandlung des Diabetes. |
| JP2675573B2 (ja) * | 1988-03-31 | 1997-11-12 | 科研製薬株式会社 | 脳機能改善剤 |
| IE61928B1 (en) * | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
-
1994
- 1994-02-03 US US08/190,924 patent/US5459164A/en not_active Expired - Lifetime
-
1995
- 1995-02-01 IL IL11251595A patent/IL112515A/xx active IP Right Grant
- 1995-02-01 PH PH49876A patent/PH31220A/en unknown
- 1995-02-02 ZA ZA95814A patent/ZA95814B/xx unknown
- 1995-02-03 AU AU17362/95A patent/AU694761B2/en not_active Ceased
- 1995-02-03 CN CN95192226A patent/CN1070698C/zh not_active Expired - Fee Related
- 1995-02-03 PT PT95909382T patent/PT814788E/pt unknown
- 1995-02-03 KR KR1019960704203A patent/KR100339874B1/ko not_active Expired - Fee Related
- 1995-02-03 CA CA002182620A patent/CA2182620C/en not_active Expired - Fee Related
- 1995-02-03 JP JP7520676A patent/JPH10503166A/ja active Pending
- 1995-02-03 EP EP95909382A patent/EP0814788B1/en not_active Expired - Lifetime
- 1995-02-03 ES ES95909382T patent/ES2166817T3/es not_active Expired - Lifetime
- 1995-02-03 DK DK95909382T patent/DK0814788T3/da active
- 1995-02-03 DE DE69522716T patent/DE69522716T2/de not_active Expired - Lifetime
- 1995-02-03 WO PCT/US1995/001190 patent/WO1995020949A1/en not_active Ceased
- 1995-02-03 AT AT95909382T patent/ATE205390T1/de not_active IP Right Cessation
- 1995-03-02 TW TW084101992A patent/TW314466B/zh not_active IP Right Cessation
-
1997
- 1997-03-04 US US08/696,984 patent/US5942549A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH10503166A (ja) | 1998-03-24 |
| ZA95814B (en) | 1995-08-03 |
| AU1736295A (en) | 1995-08-21 |
| IL112515A (en) | 2000-07-26 |
| AU694761B2 (en) | 1998-07-30 |
| CA2182620C (en) | 2007-01-16 |
| PH31220A (en) | 1998-05-05 |
| CN1144479A (zh) | 1997-03-05 |
| EP0814788A4 (en) | 1999-05-06 |
| IL112515A0 (en) | 1995-12-08 |
| CN1070698C (zh) | 2001-09-12 |
| TW314466B (https=) | 1997-09-01 |
| US5459164A (en) | 1995-10-17 |
| WO1995020949A1 (en) | 1995-08-10 |
| EP0814788B1 (en) | 2001-09-12 |
| ATE205390T1 (de) | 2001-09-15 |
| DE69522716D1 (de) | 2001-10-18 |
| PT814788E (pt) | 2002-03-28 |
| US5942549A (en) | 1999-08-24 |
| CA2182620A1 (en) | 1995-08-10 |
| DK0814788T3 (da) | 2001-11-19 |
| KR100339874B1 (ko) | 2002-11-22 |
| ES2166817T3 (es) | 2002-05-01 |
| EP0814788A1 (en) | 1998-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69522716T2 (de) | Verbesserung der glukosetoleranz | |
| DE69721833T2 (de) | Verwendung von sibutramine analogen zur senkung des fettspiegels | |
| CN1188120C (zh) | 治疗饮食紊乱的方法 | |
| EP0128482B1 (de) | Neue galenische Zubereitungsformen von oralen Antidiabetika und Verfahren zu ihrer Herstellung | |
| DE69721838T2 (de) | 1-[1-(4-chlorphenyl)cyclobutyl]-3-methylbutyl amin derivate zur senkung von harnsäurespiegeln beim menschen | |
| DE69720778T2 (de) | ARZNEIMITTEL ZUR VERZÖGERTEN FREISETZUNG DES HMG-CoA REDUKTASE INHIBITORS FLUVASTATIN | |
| EP1165081B1 (de) | Verfahren zum herstellen tolperison-enthaltender pharmazeutischer zubereitungen zur oralen verabreichung | |
| DE69824313T2 (de) | Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen | |
| JP2001503737A (ja) | 糖尿病の発生を防止するためのシブトラミン類似体の利用 | |
| DE68902531T2 (de) | Dispergierbare zubereitung. | |
| DE3720493A1 (de) | Arzneizubereitungen mit mikronisierten ebselen-kristallen | |
| DE60019914T2 (de) | Verwendung von Sibutramin oder dessem Derivat zur Behandlung von Schlafstörungen | |
| EP0035597A2 (de) | Pharmazeutische Zubereitungen | |
| EP0641200B1 (de) | 2-arylpropionsäure-zubereitungen und verfahren zu ihrer herstellung | |
| EP0669826B1 (de) | (-)-metrifonat enthaltendes arzneimittel | |
| EP0281608A1 (de) | Hydroxyindolderivat. | |
| CN1352552A (zh) | 关于骨关节炎的治疗 | |
| DE3511236A1 (de) | Praeparat mit synergistischer bronchienerweiternder wirkung und verfahren zu dessen herstellung | |
| CH669524A5 (https=) | ||
| JP2002535273A (ja) | 禁煙の支援方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: ABBOTT GMBH & CO. KG, 65205 WIESBADEN, DE |